Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens-Reference-Cited by-同舟云学术

Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens

Published:2018-11-19 Issue:3 Volume:75 Page:381-392
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Lin Wei-wei,Li Xi-wen,Jiao Zheng,Zhang Jin,Rao Xin,Zeng Da-yong,Lin Xin-hua,Wang Chang-lian^ORCID

Funder

the Guidance Project of Fujian Science and Technology Department

Weak Discipline Construction Project of Shanghai Municipal Health and Family Planning Commission

Young and Middle-aged Backbone Personnel Training Project of Fujian Province Health and Family Planning Commission

Science Foundation of Youths Project of Fujian Province Health and Family Planning Commission

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://link.springer.com/article/10.1007/s00228-018-2600-8/fulltext.html

Reference59 articles.

1. Glauser TA (2001) Oxcarbazepine in the treatment of epilepsy. Pharmacotherpay 21:904–919. https://doi.org/10.1592/phco.21.11.904.34513

2. Piña-Garza JE, Espinoza R, Nordli D, Bennett DA, Spirito S, Stites TE, Tang D, Sturm Y (2005) Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology 65:1370–1375. https://doi.org/10.1212/01.wnl.0000186800.18456.72

3. Johannessen SI, Battino D, Berry DJ, Bialer M, Krämer G, Tomson T, Patsalos PN (2003) Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 25:347–363. https://doi.org/10.1097/00007691-200306000-00016

4. Sattler A, Schaefer M, May TW (2015) Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy. Seizure 31:149–154. https://doi.org/10.1016/j.seizure.2015.07.018

5. Striano S, Striano P, Di Nocera P, Italiano D, Fasiello C, Ruosi P, Bilo L, Pisani F (2006) Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy. Epilepsy Res 69:170–176. https://doi.org/10.1016/j.eplepsyres.2006.01.011

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric patients with epilepsy: Model‐based dose optimization;Basic & Clinical Pharmacology & Toxicology;2024-03-20

2. Pharmacogenetics and Oxcarbazepine in Children and Adolescents: Beyond HLA-B*15:02;Journal of Child and Adolescent Psychopharmacology;2024-02-01

3. Population pharmacokinetics of topiramate in Chinese children with epilepsy;European Journal of Clinical Pharmacology;2023-08-19

4. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy;European Journal of Pediatrics;2023-07-26

5. Population pharmacokinetics and exposure-safety of lipophilic conjugates prodrug DP-VPA in healthy Chinese subjects for dose regime exploring;European Journal of Pharmaceutics and Biopharmaceutics;2023-07